The present invention relates to novel benzo[d]isothiazolic-3(2H)-one-1,1-dioxide core compounds able to effectively and selectively inhibiting the IX and XII isoforms of the enzyme carbonic anhydrase (CA), which are predominantly expressed in hypoxic and metastatic tumors.
The object of the present invention is the design, synthesis, and pharmacological evaluation of novel diphenylmethane core molecules, capable of simultaneously promoting activation of the autophagy process and lipid catabolism, both in vitro and in vivo. Their dual activity may represent [...]
The present invention concerns the development of new derivatives with apoptosis-modulating action by inhibition of the MDM2/p53 complex.
The present invention relates to new synthetic analogs of Xanthohumol (XN), a naturally occurring prenylated chalcone found in the female inflorescence of the hop plant (Humulus lupulus L. - Cannabaceae). Xanthohumol is a flavonoid known for its multiple properties
The invention aims to the development of new synthetic analogs of 3-iodothyronamine (T1AM), an exponent of a class of endogenous molecules derived from thyroid hormones. The possible
The present invention belongs to the field of therapeutic treatments of cancer diseases, particularly solid tumors such as melanoma, cancers of the gastrointestinal tract and thyroid carcinoma. The use of a melanocortin 4 receptor antagonist offers a possible new target [...]
The present innovation refers to the field of bioeconomy, using biological materials of industrial waste for phytopharmaceutical use.
